Inflammatory Bowel Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The inflammatory bowel therapeutics market size is expected to grow from USD 27.43 billion in 2025 to USD 28.95 billion in 2026 and is forecast to reach USD 37.92 billion by 2031 at 5.55% CAGR over 2026-2031. This report is Segmented by Disease (Crohn's Disease and Ulcerative Colitis), Drug Class (TNF Inhibitors, JAK Inhibitors and More), Moelcule Type (Biologics, Biosimiliar and More), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Inflammatory Bowel Therapeutics Market Trends and Insights

Intensifying Late-Stage Pipeline for Anti-IL-23 & TL1A

Anti-IL-23 drugs are displacing legacy TNF blockers as Phase 3 data confirm superior endoscopic remission rates; risankizumab achieved 31.8% at week 48 versus ustekinumab’s 16.2% in a head-to-head trial. The European regulator issued a positive opinion for risankizumab in ulcerative colitis, setting the stage for a continent-wide launch. Eli Lilly’s mirikizumab is in late-stage testing alongside tirzepatide to address obesity comorbidities, underscoring the market’s move toward multi-disease management. TL1A inhibitors are moving through proof-of-concept studies as drug makers strive for intestine-specific anti-inflammatory action without systemic immune suppression. These combined efforts are set to reshape treatment algorithms and reallocate revenue streams within the inflammatory bowel disease (IBD) therapeutics market.

Rapid Uptake of Oral JAK Inhibitors in Moderate-to-Severe UC & CD

Oral JAK inhibitors have broken the injection barrier that discouraged some patients from initiating biologic therapy. Tofacitinib and upadacitinib deliver efficacy comparable to infusion-based biologics, while copay savings programs cut out-of-pocket costs for eligible patients. The United States FDA has refined the REMS program to balance vigilance with prescriber convenience, and real-world data are clarifying cardiovascular and malignancy risk profiles in IBD populations. Pediatric trials of etrasimod in adolescents signal that the addressable pool will grow as age restrictions fall. This convergence of clinical data, patient demand, and payer support is translating into a materially higher growth contribution from oral therapies to the inflammatory bowel disease (IBD) therapeutics market.

Stringent REMS & Boxed Warnings for JAK Class

Uptake of JAK inhibitors faces regulatory friction as prescribers must counsel patients on cardiovascular, malignancy, and thrombosis risks under the FDA’s REMS program. The boxed warnings are particularly restrictive for elderly or comorbid populations, slowing first-line adoption in these cohorts. Although accumulating real-world data may soften these constraints over time, the near-term drag favors IL-23 agents and gut-selective mechanisms, trimming potential growth for the inflammatory bowel disease therapeutics market.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Treat-to-Target Guidelines Boosting Early Biologic Use
• Mainstream Biosimilar Penetration Driving Patient Access
• High Biologic Pricing Pressure From Payers & HTA Bodies

Segment Analysis

Revenue from Crohn’s disease is projected to climb at an 8.32% CAGR to 2031, overtaking overall market pace despite ulcerative colitis’ 51.68% revenue dominance in 2025. The crohn’s-specific inflammatory bowel disease therapeutics market size for pediatric patients is enlarging as pharmacokinetic studies in children as young as two demonstrate safe dosing of risankizumab. Combination regimens that pair an anti-integrin with a JAK inhibitor have yielded superior endoscopic healing in refractory cases, further lifting average treatment spend.

Persistent mucosal damage and higher surgical rates push clinicians to adopt early biologic intervention in Crohn’s disease, and insurers are gradually approving top-down protocols. The disease’s heterogeneity raises per-patient monitoring costs, but also creates headroom for premium-priced precision therapies. Ulcerative colitis, by contrast, benefits from a clearer disease course and an expanding lineup of effective oral agents, including newly approved mirikizumab. Treatment personalization, spanning dual biologic approaches as well as comorbidity management, is set to raise lifetime revenue per Crohn’s patient within the inflammatory bowel disease therapeutics market.

TNF inhibitors held a 35.95% inflammatory bowel disease therapeutics market share in 2025 even as biosimilar erosion intensified. Skyrizi and Rinvoq revenues leapt to USD 17.689 billion in 2024, exemplifying how carefully sequenced portfolio hand-offs can cushion the erosion of legacy assets. JAK inhibitors, growing at a 6.85% CAGR, marry oral convenience with increasingly favorable safety packages and are progressively tested in younger cohorts.

Interleukin inhibitors, particularly IL-23 agents, are positioned for step-change adoption once broad reimbursement starts in Europe and Japan. Anti-integrins continue to serve patients who prefer gut-selective targeting, and research into TL1A antagonists is adding another mechanism to the therapeutic mix. Meanwhile, PHD inhibitors such as ISM5411 are carving out a future niche as gut-restricted small molecules, indicating that mechanistic diversification will remain central to competitiveness within the inflammatory bowel disease therapeutics market.

Complete Report Scope:

• By Disease
  • Crohn’s Disease
  • Ulcerative Colitis
• By Drug Class
  • TNF Inhibitors
  • JAK Inhibitors
  • IL Inhibitors
  • Anti-integrins
  • Aminosalicylates
  • Corticosteroids
  • Other Classes
• By Molecule Type
  • Biologics
  • Small-Molecule Therapies
  • Biosimilars
• By Route of Administration
  • Parenteral
  • Oral
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America controlled 35.84% of global revenue in 2025 on the back of advanced health-care infrastructure, strong insurance coverage, and rapid product launches through the FDA’s breakthrough designation pathway. Uptake of Skyrizi and Rinvoq, which booked USD 17.689 billion in combined sales, demonstrates how quickly prescribers migrate to new mechanisms when supported by robust real-world evidence. Copay assistance remains essential, yet 29 states still allow accumulator programs that can blunt the benefit of manufacturer coupons, prompting ongoing patient-advocacy efforts.

Europe ranks second by value but leads the world in biosimilar adoption, creating a price-competitive environment that compresses margins yet expands patient reach. The EMA’s positive CHMP opinion for risankizumab in ulcerative colitis is expected to accelerate IL-23 growth, whereas HTA bodies continue to challenge incremental innovation premiums, directing companies toward outcomes-based contracts. Post-marketing safety registries are especially developed, informing global regulatory revisions and underpinning payer negotiations.

Asia-Pacific is forecast for the highest regional CAGR at 8.21% through 2031, propelled by regulatory harmonization and public-sector investment in specialty care. Japan’s biotechnology revitalization strategy includes funding for local startups and expedited review pathways, while China’s retrospective study of ustekinumab reports 75% remission rates in pediatric Crohn’s disease cohorts. India is emerging as a CDMO alternative under the US Biosecure Act, appealing to multinationals wary of supply-chain concentration in China. These developments collectively add depth and resilience to the inflammatory bowel disease therapeutics market across Asia-Pacific.

Middle East and Africa, though smaller in absolute terms, deliver long-run upside thanks to young demographics and improving specialty-care access. GCC governments are building IBD centers of excellence and partnering with multinational firms for local fill-and-finish operations. South Africa’s clinical-trial capacity is drawing early-phase studies, giving the region first-hand exposure to cutting-edge therapies that could shorten launch timelines.

South America delivers steady gains as Brazil and Argentina refine their regulatory frameworks and court foreign investment. Economic volatility still pressures biologic pricing, but phased reimbursement programs and local production partnerships are increasing availability. Clinical-trial participation continues to serve as an entry strategy for companies targeting Latin America, offering compassionate-use channels for severe cases while building prescriber familiarity.

List of Companies Covered in this Report:

• Abbvie
• Johnson & Johnson
• Takeda Pharmaceuticals
• Pfizer
• Eli Lilly and Company
• Bristol-Myers Squibb
• UCB
• Amgen
• Samsung Bioepis
• Bausch Health (Salix)
• Gilead Sciences
• Arena Pharmaceuticals
• Celltrion Healthcare
• Galapagos NV
• Merck
• Abivax
• Aurobindo
• Fresenius
• Sun Pharmaceuticals Industries
• Zydus Lifesciences

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support